Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy (Q48228997)

9 February 2018

title

Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy (English)

1 reference

9 February 2018

author

Jürgen Burhenne

4

1 reference

9 February 2018

Walter E Haefeli

5

1 reference

9 February 2018

Gerd Mikus

6

1 reference

9 February 2018

author name string

S Katzenmaier

1

1 reference

9 February 2018

C Markert

2

1 reference

9 February 2018

K-D Riedel

3

1 reference

9 February 2018

language of work or name

English

0 references

publication date

21 September 2011

1 reference

9 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

9 February 2018

volume

90

1 reference

9 February 2018

issue

5

1 reference

9 February 2018

page(s)

666-673

1 reference

9 February 2018

Hospital admissions resulting from preventable adverse drug reactions

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Admissions to a medical intensive care unit related to adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Pharmacokinetics of midazolam in anaesthetized cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

Measuring agreement in method comparison studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

What happens to long-term medication when general practice patients are referred to hospital?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.164

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.164

1 reference

9 February 2018

release_y6bu4sanu5dwrk2apwvaontv4y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y6bu4sanu5dwrk2apwvaontv4y

24 November 2022

mapped directly with Wikidata item

1 reference

9 February 2018